Scholar
Marketplace
Lab
Feedback
$
English
Sign In
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis.
Translate
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Български
Catalan
Cebuano
中文(简体)
中文(繁體)
Corsican
Czech
Danish
Dutch
English
Esperanto
Estonian
Finnish
Français
Georgian
Deutsch
Greek
Haitian Creole
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Kazakh
Khmer
Korean
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malay
Maltese
Maori
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Romanian
Russian
Samoan
Serbian
Sinhala
Slovak
Slovenian
Somali
Spanish
Swahili
Swedish
Tajik
Tamil
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Xhosa
Zulu
Phillip Muckett
Alice Pollard
Tera R Kent
Lucy Penfold
David Carling
+4 authors
Journal:
2018/November
-
Cancer Research
ISSN:
1538-7445
PUBMED:
30242113
DOI:
10.1158/0008-5472.CAN-18-0585
Abstract:
New targets are required for treating prostate cancer, particularly castrate-resistant disease. Previous studies reported that calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) expression is increased in human prostate cancer. Here, we show that Camkk2 deletion or pharmacologic inhibition protects against prostate cancer development in a preclinical mouse model that lacks expression of prostate-specific Pten. In contrast, deletion of AMP-activated protein kinase (Ampk) β1 resulted in earlier onset of adenocarcinoma development. These findings suggest for the first time that Camkk2 and Ampk have opposing effects in prostate cancer progression. Loss of CAMKK2 in vivo or in human prostate cancer cells reduced the expression of two key lipogenic enzymes, acetyl-CoA carboxylase and fatty acid synthase. This reduction was mediated via a posttranscriptional mechanism, potentially involving a decrease in protein translation. Moreover, either deletion of CAMKK2 or activation of AMPK reduced cell growth in human prostate cancer cells by inhibiting de novo lipogenesis. Activation of AMPK in a panel of human prostate cancer cells inhibited cell proliferation, migration, and invasion as well as androgen-receptor signaling. These findings demonstrate that CAMKK2 and AMPK have opposing effects on lipogenesis, providing a potential mechanism for their contrasting effects on prostate cancer progression in vivo They also suggest that inhibition of CAMKK2 combined with activation of AMPK would offer an efficacious therapeutic strategy in treatment of prostate cancer.Significance: These findings show that CAMKK2 and its downstream target AMPK have opposing effects on prostate cancer development and raise the possibility of a new combined therapeutic approach that inhibits CAMKK2 and activates AMPK. Cancer Res; 78(24); 1-15. ©2018 AACR.
Open in
PUBMED
|
DOI
|
Google Scholar
|
Wikipedia
Relations:
Citations
(7)
Genes
(4)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.
Drag-and-drop any entity to your messages.
Learn More
Search and select entities to see details here. Details will include lists of related entities (via publication). Explore related entities further.
Learn More